Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery

2014 ◽  
Vol 29 (6) ◽  
pp. 553-563 ◽  
Author(s):  
Francesco Franchi ◽  
Fabiana Rollini ◽  
Dominick J. Angiolillo
Author(s):  
F. W. A. Verheugt ◽  
P. Damman ◽  
S. A. J. Damen ◽  
J. J. Wykrzykowska ◽  
E. C. I. Woelders ◽  
...  

AbstractFor secondary prevention of coronary artery disease (CAD) antiplatelet therapy is essential. For patients undergoing a percutaneous coronary intervention (PCI) temporary dual antiplatelet platelet therapy (DAPT: aspirin combined with a P2Y12 blocker) is mandatory, but leads to more bleeding than single antiplatelet therapy with aspirin. Therefore, to reduce bleeding after a PCI the duration of DAPT is usually kept as short as clinically acceptable; thereafter aspirin monotherapy is administered. Another option to reduce bleeding is to discontinue aspirin at the time of DAPT cessation and thereafter to administer P2Y12 blocker monotherapy. To date, five randomised trials have been published comparing DAPT with P2Y12 blocker monotherapy in 32,181 stented patients. Also two meta-analyses addressing this novel therapy have been presented. P2Y12 blocker monotherapy showed a 50–60% reduction in major bleeding when compared to DAPT without a significant increase in ischaemic outcomes, including stent thrombosis. This survey reviews the findings in the current literature concerning P2Y12 blocker monotherapy after PCI.


Platelets ◽  
2014 ◽  
Vol 26 (6) ◽  
pp. 593-597 ◽  
Author(s):  
Bernadeta Chyrchel ◽  
Justyna Totoń-Żurańska ◽  
Olga Kruszelnicka ◽  
Michał Chyrchel ◽  
Waldemar Mielecki ◽  
...  

1998 ◽  
Vol 88 (5) ◽  
pp. 1233-1239 ◽  
Author(s):  
Manfred D. Seeberger ◽  
Karl Skarvan ◽  
Peter Buser ◽  
Wolfgang Brett ◽  
Reinhard Rohlfs ◽  
...  

Background A cardiac risk stratification test that can be performed during operation would be expected to give valuable information for the therapeutic management of patients who need urgent noncardiac surgery. This study was designed to evaluate the feasibility and safety of a dobutamine-atropine stress protocol to detect inducible demand ischemia in anesthetized patients. Methods A standard dobutamine-atropine stress protocol was performed in 80 patients with severe coronary artery disease during fentanyl-isoflurane anesthesia. Biplane transesophageal echocardiography and 12-lead electrocardiography were used to detect induced ischemia. After dobutamine testing, esmolol, nitroglycerin, or both were used to revert ischemia and any hemodynamic changes, as appropriate. Results The protocol detected inducible ischemia or achieved the target heart rate in 75 of the 80 (94%) patients. None of the prospectively defined adverse outcomes, such as cardiovascular collapse, severe ventricular arrhythmia, persistent (> or =5 min) ischemia, or hemodynamic instability, occurred in any of the patients. Ischemia was induced and detected in 73 of the 80 (91%) patients. Conclusion Dobutamine stress echocardiography is feasible in anesthetized patients with severe coronary artery disease. The lack of serious complications and the high sensitivity to detect inducible ischemia in this patient population provide the basis for further evaluation of the safety and diagnostic value of dobutamine stress echocardiography during general anesthesia in larger studies of patients at risk for coronary artery disease undergoing noncardiac surgery.


Sign in / Sign up

Export Citation Format

Share Document